Zobrazeno 1 - 10
of 189
pro vyhledávání: '"Christopher M Blanchette"'
Publikováno v:
Drugs in Context, Pp 1-14 (2016)
Background: Although a number of monoimmunotherapies and targeted therapies are available to treat BRAF+ advanced melanoma, response rates remain relatively low in the range of 22–53% with progression-free survival (PFS) in the range of 4.8–8.8 m
Externí odkaz:
https://doaj.org/article/ed0cccff9bed421392946efa58855a26
Autor:
Michele Wilson, Benjamin Gutierrez, Steve J Offord, Christopher M Blanchette, Anna Eramo, Stephanie Earnshaw, Siddhesh A Kamat
Publikováno v:
Drugs in Context, Pp 1-10 (2016)
Background: Schizophrenia is associated with high direct healthcare costs due to progression of disease and frequent occurrence of relapses. Aripiprazole once-monthly (AOM) has been shown to reduce total psychiatric hospitalizations among patients wh
Externí odkaz:
https://doaj.org/article/3029300f7a7a4bd4a664fbe9af199c17
Autor:
Christopher M Blanchette, Caihua Liang, Deborah P Lubeck, Britt Newsome, Sandro Rossetti, Xiangmei Gu, Benjamin Gutierrez, Nancy D Lin
Publikováno v:
Drugs in Context, Pp 1-15 (2015)
Background: Autosomal dominant polycystic kidney disease (ADPKD) is a progressive genetic disorder characterized by the development of numerous kidney cysts that result in kidney failure. Little is known regarding the key patient characteristics and
Externí odkaz:
https://doaj.org/article/0b64a6915b95424b88f616d15199c083
Autor:
Christopher M Blanchette, Anthony P Nunes, Nancy D Lin, Kathleen M Mortimer, Joshua Noone, Krishna Tangirala, Stephen Johnston, Benjamin Gutierrez
Publikováno v:
Drugs in Context, Pp 1-10 (2015)
Background: Risk evaluation and mitigation strategies (REMS), as mandated by the US Food and Drug Administration (FDA) for medications with the potential for harm, are increasingly incorporating rigid protocols for patient evaluation, but little is k
Externí odkaz:
https://doaj.org/article/73c170ca39f74d3bac1caac9f553ca56
Publikováno v:
Drugs in Context, Pp 1-14 (2015)
Objective: To characterize the frequency, cost, and hospital-reported outcomes of cachexia and debility in children and adolescents with complex chronic conditions (CCCs). Methods: We identified children and adolescents (aged ≤20 years) with CCC
Externí odkaz:
https://doaj.org/article/c280bb38f18648db91d8898035f48775
Publikováno v:
Drugs in Context, Pp 1-11 (2014)
Background: Cachexia is a condition characterized as a loss in body mass or metabolic dysfunction and is associated with several prevalent chronic health conditions including many cancers, COPD, HIV, and kidney disease, with between 10 and 50% of pat
Externí odkaz:
https://doaj.org/article/a2561eafb5644639a852551cbce2a79a
Publikováno v:
Drugs in Context, Pp 1-5 (2013)
Background: In this era of comparative effectiveness research, new, advanced techniques are being investigated by the research community to overcome the limitations of existing data sources. We describe the approach of probabilistic data linkage as a
Externí odkaz:
https://doaj.org/article/034497409c9c4f52b6a1680db46e5454
Publikováno v:
International Journal of COPD, Vol 2011, Iss default, Pp 73-81 (2011)
Christopher M Blanchette1, Melissa H Roberts1, Hans Petersen1, Anand A Dalal2, Douglas W Mapel31Division of Clinical and Outcomes Research, Lovelace Respiratory Research Institute, Kannapolis, NC, USA; 2US Health Outcomes, GlaxoSmithKline, Research T
Externí odkaz:
https://doaj.org/article/9bf1014fe7d9497a941242d6cb19cbca
Autor:
Nina Kim, Joaquin Estrada, Isabella Chow, Aleksandrina Ruseva, Abhilasha Ramasamy, Chakkarin Burudpakdee, Christopher M Blanchette
Publikováno v:
ClinicoEconomics and Outcomes Research.
Nina Kim,1 Joaquin Estrada,2 Isabella Chow,2 Aleksandrina Ruseva,1 Abhilasha Ramasamy,1 Chakkarin Burudpakdee,1 Christopher M Blanchette1 1Novo Nordisk, Inc, Plainsboro, NJ, USA; 2IQVIA, Inc, San Francisco, CA, USACorrespondence: Aleksandrina Ruseva,
Autor:
Glenda Stone, Charlie Strange, Christopher M. Blanchette, Robert A. Sandhaus, M. Chris Runken, Reuben Howden
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease. 15:2389-2397
Introduction Alpha-1 antitrypsin deficiency (AATD) is often not identified in patients with chronic obstructive pulmonary disease (COPD) until advanced stages of disease, despite the availability of genetic testing. While clinical practice guidelines